A Boston-area biotech company is cutting a fifth of its staff as it narrows its focus to a single experimental eye cancer treatment. Aura Biosciences plans to lay off 20% of its workforce, a move that will affect roughly 23 of its 113 full-time employees, as the company tightens its focus on ocular oncology and works to stretch its cash reserves for years to come.
The cuts were first reported by Boston Business Journal, and the company expects to incur between $2.9 million and $3.2 million in restructuring charges as a result. According to Fierce Biotech, the reduction is part of a broader corporate realignment designed to lower operating costs and sharpen the company's focus on its core pipeline. Aura reported $323.8 million in cash, cash equivalents, and marketable securities as of June 30, and the company says the workforce reduction and restructuring will extend its operating cash runway into the first half of 2029, per the same account.
Betting the Company on a Single Eye Cancer Drug
Aura's remaining resources are now trained on belzupacap sarotalocan, known as bel-sar, its lead drug candidate for early choroidal melanoma. The company recently completed full enrollment of 108 patients in its Phase 3 CoMpass trial testing the drug, with topline data expected in the second half of 2027, the report notes. The trial is being conducted under a Special Protocol Assessment from the FDA to support a potential approval down the line.
Choroidal melanoma is the most common primary eye cancer in adults, affecting approximately 9,000 patients annually across North America and Europe, according to Aura Biosciences. Standard radiotherapy for the disease frequently causes severe and irreversible vision loss, which is part of what makes bel-sar's tumor-targeting approach — designed to spare surrounding eye tissue — significant for patients facing few alternatives.
A Promising Bladder Cancer Program Gets Sidelined
The strategic refocus comes at a cost to other parts of Aura's pipeline. The company is deprioritizing its non-muscle invasive bladder cancer program despite interim Phase 1b/2 data showing an 81% objective response rate, according to reporting from BioSpace. Analysts expect Aura may eventually pursue out-licensing for that asset rather than continue funding it internally.
The market reaction was swift. Following the announcement, financial analyst firm H.C. Wainwright adjusted its price target on Aura stock down to $18 from $24, as noted by TipRanks. Aura also reported a net loss of $45.6 million for the second quarter of 2026 as quarterly research and development expenses climbed to $30.7 million.
New Leadership Reshapes the C-Suite
The restructuring includes a management overhaul under CEO Natalie Holles, who took over in April 2026 after the company had previously pursued broader solid tumor applications. Aura is appointing a new Chief Operating Officer and transitioning its current Chief Financial Officer into a consulting role as part of the shakeup.
The moves follow an August 5 special meeting where Aura stockholders approved a charter amendment increasing the company's authorized common stock from 150 million to 500 million shares, a step that expands the company's potential equity financing tools. Over 89 million shares were represented at that vote, which also amended Aura's stock option plan.
Part of a Wider Massachusetts Biotech Squeeze
Aura's layoffs land amid a wave of workforce reductions rippling through the biotech sector in August 2026, including local cuts at Boston-based Ensoma and earlier reductions this year at Takeda Pharmaceuticals, which eliminated 247 Massachusetts jobs, according to Fierce Biotech's tracking. The pattern reflects companies nationwide conducting what industry watchers describe as surgical restructurings to conserve cash amid long clinical timelines.
The trend has deeper roots in the state's biopharma economy. Massachusetts biopharma research and development employment fell 1.7% in 2024, marking the state's first R&D job contraction in recent memory, according to trade group MassBio. Venture capital funding to Massachusetts-headquartered biotechs also dropped 17% year-over-year in the first half of 2025, reaching its lowest level since 2017, even though the state still attracted nearly 23% of all U.S. biotech venture capital during that period.
